Stacy Cline Amin, Partner, Morrison & Foerster LLP; Former FDA Chief Counsel & HHS Deputy General Counsel
Dan Troy, Managing Director, Berkeley Research Group; Former FDA Chief Counsel
Matt Wetzel, Partner, Goodwin Procter LLP
The government’s implementation of the Inflation Reduction Act’s (IRA) Drug Price Negotiation Program is in full swing. Eight constitutional and statutory challenges to the Program are proceeding, with one court refusing four business associations’ request to preliminarily enjoin the process. Our panel of experts will discuss where things stand on the “negotiation” side and identify developments to watch for, while also discussing the lawsuits’ status and the strength of their claims.